Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.32 |
| ▸ | NSD2 | O96028 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.31 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.31 |
| ▸ | CA5A | P35218 | 1/20 | 0.31 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
| ▸ | GAPDH | P04406 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.30 |
| ▸ | BAX | Q07812 | 1/20 | 0.30 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2172863 | 0.77 | LTA4H (0.40) | LTA4HTSHRCA4NR1H2BAX | |
| SCHEMBL4452080 | 0.77 | TSHR (0.38) | LTA4HTSHRCA4KCNA3 | |
| SCHEMBL20258645 | 0.74 | CYP3A4 (0.38) | — | |
| SCHEMBL8348469 | 0.74 | KCNA3 (0.41) | TSHRKCNA3KCNH2 | |
| SCHEMBL1726433 | 0.73 | GABRA1 (0.34) | LTA4HCA4 | |
| SCHEMBL195903 | 0.72 | LTA4H (0.43) | LTA4HTSHRCA4KCNA3CA5A | |
| SCHEMBL4460772 | 0.70 | PPARA (0.35) | LTA4HCA4 | |
| SCHEMBL11402161 | 0.70 | NPC1 (0.36) | LTA4HTSHRCA4 | |
| SCHEMBL6800358 | 0.68 | LTA4H (0.39) | LTA4HTSHRCA4KCNA3NSD2 | |
| SCHEMBL11704235 | 0.68 | TSHR (0.38) | LTA4HTSHRCA4KCNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9279085-B2 | Method for the production of monofunctionalized dialkylphosphinic acids, esters and salts, and use thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2016-03-08 | — | — | US | disclosed |
| EP-2379572-B1 | METHOD FOR THE PRODUCTION OF MONOFUNCTIONALIZED DIALKYLPHOSPHINIC ACIDS, ESTERS, AND SALTS, AND USE THEREOF | CLARIANT INT LTD (CH) | 2015-12-23 | — | — | EP | disclosed |
| US-9035088-B2 | Method for producing mono-aminofunctionalized dialkylphosphinic acids and esters and salts thereof by means of acrylnitriles and use thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2015-05-19 | — | — | US | disclosed |
| US-8604108-B2 | Method for producing mono-hydroxyfunctionalized dialkylphosphinic acids and esters and salts thereof by means of acroleins and use thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2013-12-10 | — | — | US | disclosed |
| EP-2379572-A1 | METHOD FOR THE PRODUCTION OF MONOFUNCTIONALIZED DIALKYLPHOSPHINIC ACIDS, ESTERS, AND SALTS, AND USE THEREOF | Clariant International Ltd. (CH) | 2011-10-26 | — | — | EP | disclosed |
| US-20110251315-A1 | Method for the Production of Monofunctionalized Dialkylphosphinic Acids, Esters and Salts, and Use Thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2011-10-13 | — | — | US | disclosed |
| US-20110237720-A1 | Method for Producing Dialkylphosphinic Acids and Esters and Salts Thereof by Means of Vinyl Compounds and Use Thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2011-09-29 | — | — | US | disclosed |
| US-20110224339-A1 | Method for Producing Mono-Hydroxyfunctionalized Dialkylphosphinic Acids and Esters and Salts Thereof By Means of Acroleins and Use Thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2011-09-15 | — | — | US | disclosed |
| US-20110213061-A1 | Method for Producing Mono-Aminofunctionalized Dialkylphosphinic Acids and Esters and Salts Thereof and Use Thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2011-09-01 | — | — | US | disclosed |
| US-20110213062-A1 | Method for Producing Mono-Hydroxyfunctionalized Dialkyphosphinic Acids and Esters and Salts Thereof and Use Thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2011-09-01 | — | — | US | disclosed |
| US-20110213078-A1 | Method for Producing Mono-Aminofunctionalized Dialkylphosphinic Acids and Esters and Salts Thereof by Means of Acrylnitriles and Use Thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2011-09-01 | — | — | US | disclosed |
| US-20110213059-A1 | Method for Producing Mono-Carboxyfunctionalized Dialkylphosphinic Acids and Esters and Salts Thereof by means of Vinylenes-Nitriles and Use Thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2011-09-01 | — | — | US | disclosed |
| WO-2010069420-A1 | METHOD FOR THE PRODUCTION OF MONOFUNCTIONALIZED DIALKYLPHOSPHINIC ACIDS, ESTERS, AND SALTS, AND USE THEREOF | CLARIANT INTERNATIONAL LTD (CH) | 2010-06-24 | — | — | WO | disclosed |
| US-4829110-A | OXIDATION RESISTANCE TO BLEACHES AND DETERGENTS | SOLVAY & CIE (SOCIETE ANONYME) (BE) | 1989-05-09 | — | — | US | disclosed |
| US-4670493-A | OXIDATION RESISTANCE; PHENOLIC ANTIOXIDANT, PHOSPHONITE, SULF UR-CONTAINING STABILIZER | SOLVAY & CIE (SOCIETE ANONYME) (BE) | 1987-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110213062-A1 | Method for Producing Mono-Hydroxyfunctionalized Dialkyphosphinic Acids and Esters and Salts Thereof and Use Thereof | HAO2, HACL2, ACSL3 | LTA4H 448/4885TSHR 1746/4885CA4 174/4885 |
| US-20110213059-A1 | Method for Producing Mono-Carboxyfunctionalized Dialkylphosphinic Acids and Esters and Salts Thereof by means of Vinylenes-Nitriles and Use Thereof | ACSL3, ACSL1, ACSL6 | LTA4H 474/4885TSHR 909/4885CA4 147/4885 |
| US-20110224339-A1 | Method for Producing Mono-Hydroxyfunctionalized Dialkylphosphinic Acids and Esters and Salts Thereof By Means of Acroleins and Use Thereof | HAO2, AOC3, AOC2 | LTA4H 478/4885TSHR 965/4885CA4 409/4885 |
| US-20110213078-A1 | Method for Producing Mono-Aminofunctionalized Dialkylphosphinic Acids and Esters and Salts Thereof by Means of Acrylnitriles and Use Thereof | AOC2, AOC3, DAO | LTA4H 1221/4885TSHR 577/4885CA4 255/4885 |
| US-20110251315-A1 | Method for the Production of Monofunctionalized Dialkylphosphinic Acids, Esters and Salts, and Use Thereof | LPAR6, LPAR2, HAO2 | LTA4H 813/4885TSHR 83/4885CA4 512/4885 |
| US-20110237720-A1 | Method for Producing Dialkylphosphinic Acids and Esters and Salts Thereof by Means of Vinyl Compounds and Use Thereof | ACSL3, ACSL6, ACSL1 | LTA4H 494/4885TSHR 2065/4885CA4 151/4885 |
| US-20110213061-A1 | Method for Producing Mono-Aminofunctionalized Dialkylphosphinic Acids and Esters and Salts Thereof and Use Thereof | HAO2, ACSL1, ACSL3 | LTA4H 969/4885TSHR 752/4885CA4 230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.